Will ADMA achieve FY2026 revenue above $635M?

FY2025 revenue was $510.2M, so $635M requires 24.5% growth. ADMA grew 20% in FY2025 with ASCENIV growing 51%. The guidance implies acceleration from FY2025 growth rate, which is aggressive but supported by several factors: (1) Yield Enhancement first full year adds manufacturing capacity, (2) ASCENIV mix continues shifting upward from 70%, and (3) McKesson channel adds new distribution. However, the short seller controversy, AR concerns, and single-product dependency create downside risk. If ASCENIV growth sustains at 40%+ and ASCENIV reaches 75% of mix, $635M is achievable. Moderate probability.

The run-rate math: Q4 2025 was $139.2M annualized = $557M. To reach $635M, ADMA needs $78M incremental over FY2025. With ASCENIV at $363M growing 51%, even if ASCENIV growth decelerates to 35%, it adds ~$127M in FY2026 for total ASCENIV ~$490M. With BIVIGAM and Nabi-HB contributing ~$150M (stable or slight decline), total could reach $640M. The math works if ASCENIV growth stays above 30%. However, if channel stuffing claims have any merit and Q1/Q2 show digestion, the growth rate could disappoint. Also, management has consistently achieved guidance, which is a positive track record signal. Moderate probability.

I weight the channel stuffing risk more heavily. If BioCare/CuraScript were overordering in H2 2025, the revenue normalization could trim FY2026 by $30-50M. Even $30M trim would bring the target from $635M to needing $665M of gross revenue (to account for channel digestion in H1). The ASCENIV clinical differentiation is genuine, but the question is whether the reported revenue accurately reflects end-patient consumption or includes distributor inventory build. If inventory normalization occurs, $635M becomes challenging despite genuine product demand. The committee posture of HIGHER_SCRUTINY reflects this uncertainty.

ADMA has consistently delivered on guidance in FY2024-2025. The $635M target is ambitious but grounded in ASCENIV momentum: 51% growth, expanding payer coverage, and Yield Enhancement capacity. Management multi-year guidance framework ($635M/$775M/$1,100M) suggests confidence in the trajectory. The product economics (5.5-6x pricing premium) and clinical data (Tan et al.) support continued adoption. The biggest risk is not the product but the channel dynamics. If management is even close to right about ASCENIV growth, $635M is achievable.

The $635M target requires approximately $159M quarterly average. Q4 2025 was $139M. So ADMA needs to average $159M over four quarters, with the first quarter likely around $135-145M. This implies H2 2026 must be substantially above $160M/quarter. This back-end loading is typical for growing biopharma companies as ASCENIV adoption compounds. However, back-end loaded guidance carries higher execution risk. If Q1-Q2 disappoint, the H2 ramp required becomes very steep. Moderate probability, acknowledging execution risk.

Two key considerations: (1) ASCENIV growth trajectory is supported by genuine clinical differentiation and expanding payer coverage, not just pricing or channel effects. (2) Yield Enhancement process is a genuine manufacturing advance that adds capacity without new facilities. These structural drivers support the $635M target. The risks are channel dynamics (if BioCare/CuraScript orders normalize) and single-product dependency. But even with some channel normalization, the underlying patient demand growth should sustain 20-25% top-line growth. Moderate-to-good probability.

ASCENIV growth at 51% is the primary driver. Yield Enhancement adds capacity. Management has met prior guidance. $635M requires 24% growth which is an acceleration but supported by product momentum. Moderate probability, slight lean YES.

24% growth is an acceleration from 20%. Supported by ASCENIV momentum and Yield Enhancement, but channel stuffing risk and concentration concerns create downside. Back-end loaded delivery pattern increases execution risk. Near coin-flip with slight lean YES.

Committee found ASCENIV differentiation genuine. Management has met guidance before. Yield Enhancement is real manufacturing improvement. But 24% growth requires sustained execution and no channel disruption. Moderate probability weighted toward YES given product fundamentals.